Literature DB >> 1577051

Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects.

P A Soons1, G van den Berg, M Danhof, P van Brummelen, J B Jansen, C B Lamers, D D Breimer.   

Abstract

The effects of single dose (20 mg) and short-term (20 mg/day for 8 days) oral treatment with omeprazole on the pharmacokinetics and effects of oral nifedipine (10 mg capsule) and on gastric pH have been investigated in a randomized, double-blind, placebo-controlled cross-over study in 10 non-smoking healthy male subjects. The single dose of omeprazole had no significant effect on any pharmacokinetic parameter of nifedipine, nor on gastric pH, or blood pressure or heart rate. Short-term omeprazole treatment increased the AUC of nifedipine by 26% (95% confidence interval 9-46%), but all other pharmacokinetic parameters of nifedipine, including elimination half-life, Cmax, tmax, and recovery of the main urinary metabolite, were not significantly changed. The median gastric pH during the absorption phase of nifedipine was increased by short-term omeprazole (pH 4.2) compared to placebo treatment (pH 1.4). Blood pressure and heart rate did not differ between treatments. The interaction between nifedipine and omeprazole is not likely to be of major clinical relevance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1577051     DOI: 10.1007/bf00266355

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  34 in total

Review 1.  Analysis of nifedipine and its pyridine metabolite dehydronifedipine in blood and plasma: review and improved high-performance liquid chromatographic methodology.

Authors:  P A Soons; J H Schellens; M C Roosemalen; D D Breimer
Journal:  J Pharm Biomed Anal       Date:  1991       Impact factor: 3.935

2.  High-performance liquid chromatographic determination of the polar metabolites of nifedipine in plasma, blood and urine.

Authors:  M C Roosemalen; P A Soons; T Funaki; D D Breimer
Journal:  J Chromatogr       Date:  1991-04-19

3.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.

Authors:  T Kronbach; D Mathys; M Umeno; F J Gonzalez; U A Meyer
Journal:  Mol Pharmacol       Date:  1989-07       Impact factor: 4.436

4.  Biliary excretion of intravenous [14C] omeprazole in humans.

Authors:  T Lind; T Andersson; I Skånberg; L Olbe
Journal:  Clin Pharmacol Ther       Date:  1987-11       Impact factor: 6.875

5.  Inhibition of rat hepatic microsomal aminopyrine N-demethylase activity by benzimidazole derivatives. Quantitative structure-activity relationships.

Authors:  M Murray; A J Ryan; P J Little
Journal:  J Med Chem       Date:  1982-08       Impact factor: 7.446

6.  In vivo oxidative cleavage of a pyridine-carboxylic acid ester metabolite of nifedipine.

Authors:  T Funaki; P A Soons; F P Guengerich; D D Breimer
Journal:  Biochem Pharmacol       Date:  1989-12-01       Impact factor: 5.858

7.  Oral pharmacokinetics of omeprazole.

Authors:  C W Howden; P A Meredith; J A Forrest; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Cytochrome P-450-catalyzed dehydrogenation of 1,4-dihydropyridines.

Authors:  F P Guengerich; R H Böcker
Journal:  J Biol Chem       Date:  1988-06-15       Impact factor: 5.157

9.  Cytochrome P-450-catalyzed hydroxylation and carboxylic acid ester cleavage of Hantzsch pyridine esters.

Authors:  F P Guengerich; L A Peterson; R H Böcker
Journal:  J Biol Chem       Date:  1988-06-15       Impact factor: 5.157

10.  Inhibitory effect of omeprazole on the metabolism of midazolam in vitro.

Authors:  G Li; U Klotz
Journal:  Arzneimittelforschung       Date:  1990-10
View more
  16 in total

Review 1.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway.

Authors:  Sheng Feng; Yumi Cleary; Neil Parrott; Pei Hu; Cornelia Weber; Yongqing Wang; Ophelia Q P Yin; Jun Shi
Journal:  Eur J Clin Pharmacol       Date:  2015-03-24       Impact factor: 2.953

3.  Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions.

Authors:  Yoshiyuki Shirasaka; Jennifer E Sager; Justin D Lutz; Connie Davis; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2013-04-25       Impact factor: 3.922

Review 4.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

5.  Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.

Authors:  C K Yeung; Y Fujioka; H Hachad; R H Levy; N Isoherranen
Journal:  Clin Pharmacol Ther       Date:  2010-12-01       Impact factor: 6.875

Review 6.  Safety of potent gastric acid inhibition.

Authors:  Carlos Martín de Argila
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Pharmacokinetic drug interactions with anti-ulcer drugs.

Authors:  R D Negro
Journal:  Clin Pharmacokinet       Date:  1998-08       Impact factor: 6.447

Review 8.  Drug interactions with proton pump inhibitors.

Authors:  P Unge; T Andersson
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 9.  Drug-drug interaction profiles of proton pump inhibitors.

Authors:  Ryuichi Ogawa; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

Review 10.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.